These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 19938754)

  • 1. [Reliability of the thyroid stimulating hormone receptor antibodies level determination in diagnosing and prognosing of autoimmune hyperthyroidism].
    Aleksić AZ; Aleksić ZP; Mitov VM; Jović MJ
    Vojnosanit Pregl; 2009 Oct; 66(10):779-84. PubMed ID: 19938754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinction between autoimmune and non-autoimmune hyperthyroidism by determination of TSH-receptor antibodies in patients with the initial diagnosis of toxic multinodular goiter.
    Wallaschofski H; Orda C; Georgi P; Miehle K; Paschke R
    Horm Metab Res; 2001 Aug; 33(8):504-7. PubMed ID: 11544566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goitre: a comparison of two competitive binding assays.
    Pedersen IB; Knudsen N; Perrild H; Ovesen L; Laurberg P
    Clin Endocrinol (Oxf); 2001 Sep; 55(3):381-90. PubMed ID: 11589682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of the 2nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves' disease.
    Zimmermann-Belsing T; Nygaard B; Rasmussen AK; Feldt-Rasmussen U
    Eur J Endocrinol; 2002 Feb; 146(2):173-7. PubMed ID: 11834425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disseminated thyroid autonomy or Graves' disease: reevaluation by a second generation TSH receptor antibody assay.
    Meller J; Jauho A; Hüfner M; Gratz S; Becker W
    Thyroid; 2000 Dec; 10(12):1073-9. PubMed ID: 11201852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TSH receptor antibodies for confirming the diagnosis and prediction of remission duration, in newly diagnosed Graves' disease patients.
    Aleksić A; Aleksić Z; Stojanović M
    Hell J Nucl Med; 2009; 12(2):146-50. PubMed ID: 19675869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
    Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
    Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the 2nd generation radio-receptional assay for anti-TSH receptor antibodies (TRAb) in autoimmune thyroid diseases. Comparison with 1st generation and anti-thyroperoxidase antibodies (AbTPO).
    Giovanella L; Ceriani L; Garancini S
    Q J Nucl Med; 2001 Mar; 45(1):115-9. PubMed ID: 11456370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TSH receptor antibody (TRAb) assays based on the human monoclonal autoantibody M22 are more sensitive than bovine TSH based assays.
    Zöphel K; Roggenbuck D; von Landenberg P; Wunderlich G; Grüning T; Kotzerke J; Lackner KJ; Rees Smith B
    Horm Metab Res; 2010 Jan; 42(1):65-9. PubMed ID: 19830651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similar clinical performance of a novel chimeric thyroid-stimulating hormone receptor bioassay and an automated thyroid-stimulating hormone receptor binding assay in Graves' disease.
    Kamijo K; Murayama H; Uzu T; Togashi K; Olivo PD; Kahaly GJ
    Thyroid; 2011 Dec; 21(12):1295-9. PubMed ID: 22066477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased serum level of IL-7 in patients with active Graves' disease.
    Motylewska E; Nieć M; Siejka A; Komorowski J; Ławnicka H; Świętosławski J; Stępień H
    Cytokine; 2015 Oct; 75(2):373-9. PubMed ID: 26113403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the first fully automated immunoassay method for the measurement of stimulating TSH receptor autoantibodies in Graves' disease.
    Tozzoli R; D'Aurizio F; Villalta D; Giovanella L
    Clin Chem Lab Med; 2017 Jan; 55(1):58-64. PubMed ID: 27331310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermethod variability in TSH-receptor antibody measurement: implication for the diagnosis of Graves disease and for the follow-up of Graves ophthalmopathy.
    Massart C; Sapin R; Gibassier J; Agin A; d'Herbomez M
    Clin Chem; 2009 Jan; 55(1):183-6. PubMed ID: 19028818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-thyroid-stimulating hormone receptor antibodies determined by second-generation assay.
    Mankaï A; Toumi D; Chadli-Chaieb M; Ghedira-Besbes L; Saad F; Ouertani M; Sfar H; Jeddi M; Chaieb L; Ghedira I
    Clin Chem Lab Med; 2007; 45(1):26-9. PubMed ID: 17243910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of TSH-receptor antibody with the clinical and laboratory parameters in patients with newly diagnosed Graves' hyperthyroidism: experience from a tertiary referral center including a large number of patients with TSH-receptor antibody-negative patients with Graves' hyperthyroidism.
    Zuhur SS; Bilen O; Aggul H; Topcu B; Celikkol A; Elbuken G
    Endokrynol Pol; 2021; 72(1):14-21. PubMed ID: 32944926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of an automated TSI bridge immunoassay in the diagnosis of Graves' disease and its relationship to the degree of hyperthyroidism.
    Liu T; Zhang X; Long L; Zhou L; Chen J; Li M; Gao Y; Zhou X; Han X; Ji L
    BMC Endocr Disord; 2022 Aug; 22(1):218. PubMed ID: 36045442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical review about TRAb assay's history.
    Zöphel K; Roggenbuck D; Schott M
    Autoimmun Rev; 2010 Aug; 9(10):695-700. PubMed ID: 20594972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of three competitive immunoassays for measurement of TSH receptor antibodies in patients with Graves' disease.
    Doroudian S; Pedersen IB; Knudsen CS; Handberg A; Andersen SL
    Scand J Clin Lab Invest; 2017 Nov; 77(7):535-540. PubMed ID: 28737965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment.
    Wallaschofski H; Miehle K; Mayer A; Tuschy U; Hentschel B; Paschke R
    Horm Metab Res; 2002 Jul; 34(7):383-8. PubMed ID: 12189586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a coated-tube assay for antithyrotropin receptor antibodies in patients with Graves' disease and other thyroid disorders.
    Cardia MS; Lima N; Knobel M; Medeiros-Neto G
    Thyroid; 2004 Apr; 14(4):295-300. PubMed ID: 15142363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.